A human lung carcinoma cell line supports efficient measles virus growth and syncytium formation via a SLAM- and CD46-independent mechanism.
Measles virus (MV) propagates mainly in lymphoid organs throughout the body and produces syncytia by using signaling lymphocyte activation molecule (SLAM) as a receptor. MV also spreads in SLAM-negative epithelial tissues by unknown mechanisms. Ubiquitously expressed CD46 functions as another receptor for vaccine strains of MV but not for wild-type strains. We here show that MV grows and produces syncytia efficiently in a human lung adenocarcinoma cell line via a SLAM- and CD46-independent mechanism using a novel receptor-binding site on the hemagglutinin protein. This infection model could advance our understanding of MV infection of SLAM-negative epithelial cells and tissues.
Takeda
Makoto
M
Department of Virology, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. mtakeda@virology.med.kyushu-u.ac.jp
Tahara
Maino
M
Hashiguchi
Takao
T
Sato
Takeshi A
TA
Jinnouchi
Fumiaki
F
Ueki
Shoko
S
Ohno
Shinji
S
Yanagi
Yusuke
Y
D000818:Animals; D015703:Antigens, CD / Q000096:biosynthesis*; D002277:Carcinoma / Q000378:metabolism* / Q000821:virology*; D045744:Cell Line, Tumor; D002522:Chlorocebus aethiops; D004847:Epithelial Cells / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D015967:Gene Expression Regulation, Viral; D015726:Giant Cells / Q000821:virology*; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism* / Q000821:virology*; D008213:Lymphocyte Activation; D008459:Measles virus / Q000378:metabolism*; D051916:Membrane Cofactor Protein / Q000096:biosynthesis*; D011956:Receptors, Cell Surface / Q000096:biosynthesis*; D015398:Signal Transduction; D000071177:Signaling Lymphocytic Activation Molecule Family Member 1; D014709:Vero Cells
D015703:Antigens, CD; D051916:Membrane Cofactor Protein; D011956:Receptors, Cell Surface; D000071177:Signaling Lymphocytic Activation Molecule Family Member 1
J Immunol. 1990 Jul 1;145(1):238-45
1694203
J Virol. 1990 Feb;64(2):700-5
2153236
J Virol. 1993 Oct;67(10):6025-32
8371352
Cell. 1993 Oct 22;75(2):295-305
8402913
J Immunol. 1993 Nov 1;151(9):4614-24
8409422
J Virol. 1995 Jan;69(1):513-6
7983748
J Virol. 1998 Apr;72(4):2905-16
9525611
Arch Virol. 1998;143(2):213-25
9541608
J Virol. 1998 Nov;72(11):8690-6
9765410
Virology. 1999 Apr 10;256(2):340-50
10191199
Biken J. 1964 Jan;6:271-97
14186824
Virus Res. 2005 Mar;108(1-2):161-5
15681066
J Virol. 2005 Nov;79(22):14346-54
16254369
J Virol. 2005 Dec;79(24):15218-25
16306593
J Virol. 2006 May;80(9):4242-8
16611883
J Gen Virol. 2006 Jun;87(Pt 6):1643-8
16690929
J Gen Virol. 2006 Oct;87(Pt 10):2767-79
16963735
J Virol. 2006 Dec;80(23):11861-7
16987969
J Virol. 2007 Mar;81(6):2564-72
17182683
Arch Virol. 1999;144(9):1689-99
10542019
J Virol. 2000 May;74(9):3967-74
10756008
J Virol. 2000 May;74(9):4139-45
10756026
J Virol. 2000 Jul;74(14):6643-7
10864679
Nature. 2000 Aug 24;406(6798):893-7
10972291
J Virol. 2001 Jan;75(2):910-20
11134304
Virology. 2001 Jan 5;279(1):9-21
11145884
J Virol. 2001 May;75(9):4399-401
11287589
J Virol. 2001 May;75(10):4499-505
11312320
J Virol. 2002 May;76(10):4891-900
11967306
J Virol. 2002 Jul;76(13):6743-9
12050387
J Gen Virol. 2003 May;84(Pt 5):1189-97
12692284
Virus Res. 2003 Jul;94(1):11-6
12837552
J Virol. 2004 Jan;78(1):302-13
14671112
J Virol. 2004 Sep;78(17):9051-63
15308701
J Gen Virol. 2004 Oct;85(Pt 10):3001-6
15448363
N Engl J Med. 1966 Sep 8;275(10):516-23
5331291
J Pediatr. 1970 Jul;77(1):59-64
5430797
N Engl J Med. 1970 Nov 19;283(21):1139-42
5474350
Clin Exp Immunol. 1973 Mar;13(3):343-57
4701743
J Infect Dis. 1973 Dec;128(6):795-9
4203079
Arch Virol. 1975;47(4):295-307
124564
J Infect Dis. 1976 Nov;134(5):463-9
792356
J Med Virol. 1981;7(2):157-62
6167670
J Gen Virol. 1985 Jul;66 ( Pt 7):1397-409
2410551
Cancer Res. 1986 Feb;46(2):798-806
3940644
Microbiol Immunol. 1986;30(10):1067-73
3796316
J Infect Dis. 1988 Aug;158(2):433-42
3042879
Cancer Res. 1990 Sep 1;50(17):5481-7
2386953